ADAMAX Research

ADAMAX research, at the time of writing, is a description of an absence. ADAMAX is sold as N-acetyl semax adamantane, a modified form of the heptapeptide Semax. No study of ADAMAX itself has been published in any indexed source, in any language ^[5]. This article does not fill the gap with parent-peptide pharmacology. The adjacent chemistry described below is presented as work on other molecules, which is what it is.

What ADAMAX is

Vendor listings describe ADAMAX as the Semax sequence Met-Glu-His-Phe-Pro-Gly-Pro carrying two modifications. The first is acetylation of the N-terminal amine, and the second is an adamantane cage attached at the C-terminus. That structure is unconfirmed by any independent source ^[5]. It appears in none of the public chemical registries searched, and PubChem returns no compound for the product name or its variants ^[5]. Vendor pages also disagree with each other on how the adamantane group is attached. This article therefore prints no molecular formula, molecular weight or CAS number for ADAMAX.

What the published literature contains

Live PubMed searches on 28 August 2026 returned zero records for "semax AND adamantane", "acetyl-semax-adamantane" and "adamantyl AND (ACTH OR melanocortin)" ^[5]. Europe PMC returned zero hits for the exact phrase "N-acetyl semax adamantane" ^[5]. There is no human study, no animal study and no in vitro study of ADAMAX in the indexed literature ^[5]. There is likewise no published pharmacokinetic, toxicology or safety record for ADAMAX ^[5].

The nearest relevant published chemistry

One peer-reviewed paper has tested an acetylated Semax on a cell-based functional endpoint and reported the result ^[1]. That work was done in vitro ^[1]. Magrì and colleagues found that the main Cu(II) complex of acetylated Semax is a distorted CuN3O chromophore with a weak apical methionine sulfur interaction ^[1]. The unmodified peptide instead forms a CuN4 chromophore, and the acetylated complex has the more positive formal redox potential ^[1]. In the form with a free amino terminus, the complex is redox-stable and unreactive toward ascorbic acid, unlike the acetylated form ^[1]. In cell work in the same paper, acetylation did not protect SH-SY5Y neuroblastoma cells from Cu(II)-induced toxicity in vitro ^[1]. The authors attribute the crucial role in that protection to the free NH2 terminus ^[1]. That failure to protect appears specific to copper rather than to metal binding in general ^[1]. Both peptides formed zinc complexes of comparable strength in vitro, and confocal imaging showed acetylation did not affect zinc influx into the same cells ^[1]. The authors close by proposing acetylated Semax as an ionophore in antibody drug conjugates, to produce dysmetallostasis in tumor cells ^[1]. That paper tested acetylated Semax, not ADAMAX. The claimed adamantane group was absent from the peptide studied ^[1].

Where the seller rationale comes from

Sellers commonly present N-terminal acetylation as protection against cleavage by aminopeptidases. The published basis for that reasoning sits on Semax analogues rather than on ADAMAX ^[2][3]. In vitro, substituting the N-terminal methionine residue changed the rate of degradation by aminopeptidases, with the alanine, glycine and threonine analogues proving more stable than Semax ^[2]. That same work reported His-Phe-Pro-Gly-Pro as the initial proteolysis product of those three analogues, not of Semax itself ^[2]. A separate in vitro study reported that Semax yields only His-Phe-Pro-Gly-Pro ^[3]. That study used leucine aminopeptidase and enzymes from nasal mucus, brain membrane fractions and rat blood ^[3]. An in vitro proteolysis study of a compound named Semax acetyl also exists ^[4]. PubMed holds no abstract for that record, so no direction or magnitude can honestly be cited from it ^[4]. None of these studies examined an adamantane-modified peptide, and none examined ADAMAX ^[2][3][4].

Sellers make two further claims for the adamantane group, that it improves blood-brain-barrier penetration and that it makes the compound more potent than Semax. Neither claim has been tested on this peptide class in the indexed literature. No adamantane-modified ACTH fragment or melanocortin peptide appears there, and the searches above returned zero for that combination ^[5]. The lipophilicity rationale is therefore a general medicinal-chemistry argument rather than a result obtained on this molecule. The group that invented Semax has no indexed publication on adamantane ^[5].

Who produced the adjacent evidence

The proteolysis and acetyl-Semax stability records come from the Institute of Molecular Genetics of the Russian Academy of Sciences ^[2][3][4]. Myasoedov NF, the inventor of Semax, is a named author on all three of those papers ^[2][3][4]. Of the groups cited here, the only one with no stake in the parent compound reported the negative in vitro result described above ^[1].

Limitations, naming hazards and research directions

A bare search for "adamax" in PubMed returns 39 records, which looks like a literature but is not one ^[5]. Those records concern AdaMax, a machine-learning optimizer, and an unrelated antidrug-antibody measure, and none concerns this peptide ^[5]. ADAMAX is also distinct from N-acetyl semax amidate, a separate compound carrying a C-terminal amide rather than an adamantane cage ^[5]. That compound has its own PubChem record, CID 172638603, formula C39H54N10O10S ^[5]. Material written about the amidate is not evidence about ADAMAX ^[5]. ADAMAX is not approved for human therapeutic use, and FDA, EMA and trial-registry searches return no record of it ^[5].

Conclusion

ADAMAX remains a scientifically uncharacterized compound with no primary literature of its own ^[5]. The nearest peer-reviewed functional test of N-terminal acetylation on a Semax peptide was negative on copper toxicity in cells ^[1]. The same paper found no effect on zinc complex strength or zinc influx in those cells ^[1]. The first useful research step on this molecule would be published structural confirmation, followed by basic in vitro characterization.

Evidence and identity FAQ

Has ADAMAX been studied in humans? No human study of ADAMAX appears in the indexed literature, and neither does any animal or in vitro study of it ^[5]. The absence also extends to published pharmacokinetic, toxicology and safety records for the molecule ^[5].

Is ADAMAX the same compound as N-acetyl semax amidate? They are two different compounds. Both are described as acetylated at the N-terminus, but the amidate carries a C-terminal amide rather than an adamantane cage ^[5]. The amidate holds its own PubChem compound record and ADAMAX holds none ^[5].

Is N-terminal acetylation known to improve a Semax-type peptide? Published work does not establish that improvement. In one in vitro study, acetylation did not protect SH-SY5Y neuroblastoma cells from copper-induced toxicity ^[1]. Zinc complex strength and zinc influx were unaffected in that same in vitro study, which tested acetylated Semax rather than ADAMAX ^[1]. A separate proteolysis record for an acetylated Semax carries no abstract, so no direction can be drawn from it ^[4].

References

1. 1

   Magrì A, Tabbì G, Giuffrida A, Pappalardo G, Satriano C, Naletova I, Nicoletti VG, Attanasio F. Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. J Inorg Biochem. 2016 Nov;164:59-69. PMID 27586814. DOI: 10.1016/j.jinorgbio.2016.08.013
2. 2

   Shevchenko KV, V'yunova TV, Nagaev IYu, Andreeva LA, Alfeeva LYu, Myasoedov NF. Proteolysis of semax analogues with different N-terminal amino acids by aminopeptidases. Bioorg Khim. 2011 Jul-Aug;37(4):475-82. PMID 22096989. DOI: 10.1134/s1068162011040133 (in Russian)
3. 3

   Shevchenko KV, V'yunova TV, Nagaev IYu, Andreeva LA, Myasoedov NF. Proteolysis of simple glyprolines by leucine aminopeptidase and enzymes from nasal slime, brain membranes, and rat blood. Bioorg Khim. 2013 May-Jun;39(3):320-5. PMID 24397030. DOI: 10.1134/s1068162013030151 (in Russian)
4. 4

   Shevchenko KV, Nagaev IY, Andreeva LA, Shevchenko VP, Myasoedov NF. Stability of Semax acetyl to proteolysis in various biological media. Dokl Biol Sci. 2013 Mar;449:110-2. PMID 23652441. DOI: 10.1134/S0012496613020166 (no abstract in the PubMed record)
5. 5

   Database search records, run live on 28 August 2026: PubMed via NCBI E-utilities (esearch counts for adamax = 39, all 39 titles retrieved, of which 38 concern the AdaMax machine-learning optimizer and one, PMID 38031738., uses ADAmax for a maximum antidrug-antibody response to an adalimumab biosimilar; semax AND adamantane = 0, acetyl-semax-adamantane = 0, adamantyl AND (ACTH OR melanocortin) = 0, Myasoedov NF[au] AND adamantane = 0); Europe PMC REST search, exact phrase "N-acetyl semax adamantane", hitCount 0; PubChem PUG-REST name lookups (adamax = PUGREST.NotFound; N-acetyl semax amidate = CID 172638603, C39H54N10O10S; semax = CID 9811102); openFDA drug/label and drug/drugsfda, EMA EPAR and withdrawn-application datasets, and ClinicalTrials.gov API v2, all returning no record for the compound. The EMA refused-applications dataset URL returned HTTP 404 and could not be checked.